A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...